Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia

NCT03639480 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension
Hyperlipidemia

Interventions

DRUG: Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
DRUG: Amlodipine 10mg+Valsartan 160mg
DRUG: Valsartan 160mg+Atorvastatin 40mg

Sponsor

HK inno.N Corporation